<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03459170</url>
  </required_header>
  <id_info>
    <org_study_id>BP-I-008</org_study_id>
    <nct_id>NCT03459170</nct_id>
  </id_info>
  <brief_title>Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant</brief_title>
  <official_title>A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellicum Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellicum Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor&#xD;
      BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD)&#xD;
      hematologic malignancies post-allogeneic transplant. The study will consist of the Main Study&#xD;
      and an optional Pharmacokinetics (PK) Sub-Study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main Study:&#xD;
&#xD;
      Approximately 16 subjects will participate in the BPX-501 main study. The treatment consists&#xD;
      of three courses of BPX-501 T cell infusions at 30 day intervals with 2 escalating dose&#xD;
      levels (DL). DL1 on Day 0; DL2 on Days 30 and 60.&#xD;
&#xD;
      Two doses of rimiducid (AP1903) will be investigated for the treatment of aGvHD after BPX-501&#xD;
      T cell infusion. A 0.1mg/kg initial dose of rimiducid which has demonstrated the ability to&#xD;
      induce &gt;50% BPX-501 T cell eradication in preclinical animal models will first be&#xD;
      administered in the event of uncontrollable aGvHD. If there is no response to this dose&#xD;
      within 24hrs + 12hrs a second dose of 0.4 mg/kg (which has been reported to induce T cell&#xD;
      eradication of &gt; 90%) will be administered. If there is no measurable GvHD response to the&#xD;
      initial dose of 0.1 mg/kg rimiducid in 2 subjects, the starting dose of rimiducid will be 0.4&#xD;
      mg/kg for all subsequent subjects.&#xD;
&#xD;
      Rimiducid (AP1903) Optional PK Sub-Study:&#xD;
&#xD;
      Approximately 12 subjects will be recruited to participate in the optional Rimiducid (AP1903)&#xD;
      PK sub-study. Subjects will be assigned to one of two arms and receive either 0.04mg/kg or&#xD;
      0.4mg/kg of Rimiducid (AP1903). Each arm will have a target enrollment of 6 subjects.&#xD;
&#xD;
        -  Arm 1: 0.04mg/kg Rimiducid (AP1903), 6 subjects;&#xD;
&#xD;
        -  Arm 2: 0.4mg/kg Rimiducid (AP1903), 6 subjects. Rimiducid PK samples and ECG data will&#xD;
           be collected at Pre-dose (0 hour), 30 minutes, 2 hours and 8 hours following the&#xD;
           initiation of rimiducid (AP1903) infusion.&#xD;
&#xD;
      Efforts shall be made to enroll at least one subject from each age subset into the PK&#xD;
      sub-study: infants and toddlers (12 months to 23 months); children (2-11 years); and&#xD;
      adolescents (12-18 years).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">July 2035</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BPX-501 Safety</measure>
    <time_frame>Month 24</time_frame>
    <description>Incidence of treatment emergent adverse events of 2 stratified dose levels of BPX-501 T cell infusions based on patient-donor match in pediatric subjects with hematologic malignancies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean plasma concentration</measure>
    <time_frame>pre- dose, 30 min, 2 hours and 8 hours after start of infusion</time_frame>
    <description>Measure plasma concentrations of rimiducid (AP1903) at two doses (Arm 1: 0.04mg/kg; Arm 2: 0.4mg/kg) in pediatric subjects, during and after a 2-hour infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Month 24</time_frame>
    <description>Measure overall survival rates after BPX-501 infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Month 24</time_frame>
    <description>Assess response rates after BPX-501 infusion;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>BPX-501 T cells and rimiducid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 3 courses of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).&#xD;
Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BPX-501 T cells</intervention_name>
    <description>Biological: T cells transduced with CaspaCIDe® safety switch</description>
    <arm_group_label>BPX-501 T cells and rimiducid</arm_group_label>
    <other_name>rivogenlecleucel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rimiducid</intervention_name>
    <description>administered to kill BPX-501 cells in the event of GVHD</description>
    <arm_group_label>BPX-501 T cells and rimiducid</arm_group_label>
    <other_name>AP1903</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged &lt; 18&#xD;
&#xD;
          -  Clinical diagnosis of one of the following pediatric hematological malignancies:&#xD;
&#xD;
               -  High-risk Acute Leukemia (Acute lymphoblastic leukemia [ALL] or acute myeloid&#xD;
                  leukemia [AML]) in any CR&#xD;
&#xD;
               -  Acute Leukemia that is minimal residual disease (MRD) positive at &gt; 1copy per 1 x&#xD;
                  10,000 reference copies pre-HSCT&#xD;
&#xD;
               -  Myelodysplastic Syndrome (MDS)&#xD;
&#xD;
               -  Hodgkin or Non-Hodgkin lymphomas&#xD;
&#xD;
               -  Other high-risk hematological malignancy in CR eligible for stem cell&#xD;
                  transplantation per institutional standard&#xD;
&#xD;
               -  Patients with a hematological malignancy who have received a prior allogeneic&#xD;
                  HSCT&#xD;
&#xD;
               -  Patients with on-treatment relapse of AML within 6 months of initial CR&#xD;
&#xD;
               -  Patients relapsing within 6 months of initial diagnosis of hematological&#xD;
                  malignancy.&#xD;
&#xD;
          -  Planned or previous treatment of hematological malignancy with one of the following:&#xD;
&#xD;
               -  Matched related HSCT&#xD;
&#xD;
               -  Mismatched related HSCT&#xD;
&#xD;
          -  For patients who have received a transplant, occurrence of one of the following &gt; 30&#xD;
             days post-HSCT:&#xD;
&#xD;
               -  Minimal residual disease (MRD) positive at &gt; 1 copy per 1 x 10,000 reference&#xD;
                  copies post-HSCT&#xD;
&#xD;
               -  Decreasing donor chimerism detected on two bone marrow biopsies or peripheral&#xD;
                  blood analyses at a &gt; 7-day interval&#xD;
&#xD;
               -  Recurrent disease&#xD;
&#xD;
          -  Life expectancy &gt;10 weeks;&#xD;
&#xD;
          -  Signed donor and patient/guardian informed consent;&#xD;
&#xD;
          -  For mismatched related donor recipients, a minimum genotypic identical match of 5/10&#xD;
             is required, as determined by high resolution typing, at least one allele of each of&#xD;
             the following genetic loci must be matched: HLA-A, HLA-B, HLA-C, HLA- DRB1, and&#xD;
             HLA-DQB1.&#xD;
&#xD;
          -  Performance status: Karnofsky/Lansky score &gt; 70%.&#xD;
&#xD;
          -  Adequate organ function as measured by:&#xD;
&#xD;
             o Bone marrow:&#xD;
&#xD;
          -  &gt; 25% donor T cell chimerism&#xD;
&#xD;
          -  ANC &gt;1 x 109/L.&#xD;
&#xD;
               -  Cardiac: LVEF at rest &gt;45%.&#xD;
&#xD;
               -  Pulmonary: FEV 1, FVC, DLCO (diffusion capacity for CO) &gt; 50% predicted&#xD;
                  (corrected for hemoglobin); for children who are unable to perform pulmonary&#xD;
                  function tests due to age or developmental ability, there must be no evidence of&#xD;
                  dyspnea or no need for supplemental oxygen as evidenced by 02 saturation ≥ 92% on&#xD;
                  room air.&#xD;
&#xD;
               -  Hepatic: direct bilirubin ≤ 3x ULN, or AST/ALT ≤ 5x ULN.&#xD;
&#xD;
               -  Renal: creatinine clearance ≤ 2x of ULN for age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        ≥ Grade II acute GVHD or moderate to severe chronic GVHD due to a previous allograft at the&#xD;
        time of screening;&#xD;
&#xD;
          -  Active CNS involvement by malignant cells (&lt; 2 months prior to time of consent);&#xD;
&#xD;
          -  Current uncontrolled bacterial, viral or fungal infection (currently taking medication&#xD;
             with evidence of progression of clinical symptoms or radiologic findings).&#xD;
&#xD;
          -  Positive HIV serology or viral RNA;&#xD;
&#xD;
          -  Pregnancy (positive serum βHCG test) or breast-feeding female;&#xD;
&#xD;
          -  Patients of reproductive age unwilling to use effective forms of birth control or&#xD;
             abstinence for a year after BPX-501 T cell infusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bellicum Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Bellicum Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Matteo Hospital</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>lymphoma</keyword>
  <keyword>minimal residual disease</keyword>
  <keyword>BPX-501</keyword>
  <keyword>AP1903</keyword>
  <keyword>rimiducid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

